BACKGROUND: This study investigates the efficacy and the feasibility of a chemotherapy regimen with topotecan plus vincristine and doxorubicin (TVD) given on an individually tailored basis to patients with refractory/recurrent rhabdomyosarcoma (RMS). PATIENTS AND METHODS: Nine patients received TVD therapy at relapse, and six were assessable for response. RESULTS: All the six patients experienced objective response after two cycles of chemotherapy: one minor response, four partial response, and one complete response. CONCLUSIONS: The value of our study is severely limited by the small number of cases, the single-institutional setting and the individually tailored treatment, but we nonetheless confirmed the feasibility and tolerability of topotecan-based chemotherapy in RMS.
BACKGROUND: This study investigates the efficacy and the feasibility of a chemotherapy regimen with topotecan plus vincristine and doxorubicin (TVD) given on an individually tailored basis to patients with refractory/recurrent rhabdomyosarcoma (RMS). PATIENTS AND METHODS: Nine patients received TVD therapy at relapse, and six were assessable for response. RESULTS: All the six patients experienced objective response after two cycles of chemotherapy: one minor response, four partial response, and one complete response. CONCLUSIONS: The value of our study is severely limited by the small number of cases, the single-institutional setting and the individually tailored treatment, but we nonetheless confirmed the feasibility and tolerability of topotecan-based chemotherapy in RMS.
Authors: J Thompson; E O George; C A Poquette; P J Cheshire; L B Richmond; S S de Graaf; M Ma; C F Stewart; P J Houghton Journal: Clin Cancer Res Date: 1999-11 Impact factor: 12.531
Authors: C F Stewart; W C Zamboni; W R Crom; A Gajjar; R L Heideman; W L Furman; W H Meyer; P J Houghton; C B Pratt Journal: Invest New Drugs Date: 1996 Impact factor: 3.850
Authors: D G Tubergen; C F Stewart; C B Pratt; W C Zamboni; N Winick; V M Santana; Z A Dryer; J Kurtzberg; B Bell; H Grier; T J Vietti Journal: J Pediatr Hematol Oncol Date: 1996-11 Impact factor: 1.289
Authors: Joanne J Lager; Elizabeth R Lyden; James R Anderson; Alberto S Pappo; William H Meyer; Philip P Breitfeld Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: R Nitschke; J Parkhurst; J Sullivan; M B Harris; M Bernstein; C Pratt Journal: J Pediatr Hematol Oncol Date: 1998 Jul-Aug Impact factor: 1.289
Authors: P J Houghton; P J Cheshire; L Myers; C F Stewart; T W Synold; J A Houghton Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333
Authors: Jörg Thomas Hartmann; R D Issels; K San Nicolo; V Grünwald; B Hertenstein; E Papesch; S Krause; I Sturm Journal: Invest New Drugs Date: 2015-07-12 Impact factor: 3.850
Authors: Federica Saletta; Carol Wadham; David S Ziegler; Glenn M Marshall; Michelle Haber; Geoffrey McCowage; Murray D Norris; Jennifer A Byrne Journal: BBA Clin Date: 2014-06-28